Arrowhead Pharmaceuticals vs Mirum Pharmaceuticals
Arrowhead Pharmaceuticals is the larger business, with $829m of revenue in fiscal 2025 against $521m for Mirum Pharmaceuticals (1.6 times as much). Arrowhead Pharmaceuticals grew faster (23258.2% against 54.7%). Arrowhead Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -0.2% against -4.5%.
| Latest fiscal year | Arrowhead PharmaceuticalsARWR, 2025 | Mirum PharmaceuticalsMIRM, 2025 |
|---|---|---|
| Revenue | $829m | $521m |
| Revenue growth | 23258.2% | 54.7% |
| Net income | −$1.6m | −$23.4m |
| Operating margin | — | -4.2% |
| Net margin | -0.2% | -4.5% |
| Return on equity | -0.5% | -8.6% |
| Free cash flow | $157m | $54.9m |
| Cash | $227m | $297m |
| Total debt | $255m | $310m |
| Debt to equity | — | 98.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 711 | 372 |
| Market value | $8.43bn | $5.61bn |
| Price vs our value range | — | — |
| Moat score | 10 (Weak) | 10 (Weak) |
| Insider trades, 12 months | 0 buys, 64 sales | 1 buys, 59 sales |